Bortezomib vs Carfilzomib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: Proteasome · full Multiple Myeloma pipeline
Bortezomib
Marketed by Takeda Pharmaceutical Company and partners
NCT00048230 · Phase 3 · completed
APEX randomized 620 patients with relapsed multiple myeloma to bortezomib or high-dose dexamethasone in an open-label design. Its primary endpoint, time to progression, is a clinical outcome and was met. An open-label trial is never graded strong under the rubric, so the grade is moderate.
Next expected readout: November 2026 · NCT06505369 (registry estimate)
Reported efficacy
Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): Number of Patients With Overall Response (Complete Response + Partial Response) (Over 4 cycles (prior to the addition of dexamethasone)): VELCADE Subcutaneuous 61/145 | VELCADE Intravenous 31/73 (met)
Result source: NCT00722566
Carfilzomib
Marketed by Amgen and partners
NCT01080391 · Phase 3 · completed
The 792 participants were randomly assigned to carfilzomib plus lenalidomide and dexamethasone or to lenalidomide and dexamethasone, but treatment was open-label rather than blinded. The primary clinical endpoint, progression-free survival, was met, with a median of 26.3 versus 17.6 months and a statistically significant difference (p<0.0001).
Next expected readout: November 2026 · NCT04973605 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Progression-free Survival (PFS) as Assessed by the Independent Review Committee (PA DCO Only) (From randomization until the PA DCO date of 14 July 2019; the longest treatment duration as of the DCO was 102.3 weeks): Kd - Carfilzomib and Dexamethasone — Participants with PFS events: 68 Participants; Participants who were censored: 86 Participants | KdD - Carfilzomib, Dexamethasone and Daratumumab — Participants with PFS events: 110 Participants; Participants who were censored: 202 Participants (met)
Result source: NCT03158688
Results for Multiple Myeloma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
PFS, median
- Bortezomib
- 11.2 vs 7.1vs BTZ+LD-DEXNCT01734928
14 other results
- 13.9 vs 9.5 NCT03110562
- 46.7 NCT02541383
- 14.7 NCT00507416
- 15.4 NCT00507416
- 17.3 NCT00507416
- 36.4 vs 19.3 NCT02195479
- 6.6 vs 8.8 NCT03110562
- 22.5 vs 22.1 NCT01539083
- 3.9 vs 8.8 NCT03110562
- 9.9 vs 12.6 NCT00813150
- 52.8 NCT02541383
- 3.9 NCT03110562
- 8.1 vs 7.6 NCT00401843
- 15.3 NCT02290431
- Carfilzomib
- 26.3 vs 17.6vs Lenalidomide and Dexamethasone (Rd)NCT01080391
35 other results
- 35.6 vs 19.1 NCT03275285
- 41.7 vs 20.8 NCT03275285
- 18.7 vs 9.4 NCT01568866
- 22.3 vs 22.1 NCT01818752
- 11.2 NCT02412878
- 7.6 NCT02412878
- 3.7 vs 3.3 NCT01302392
- 5 NCT01903811
- 8 NCT01903811
- 15.3 NCT01677858
- 16.2 NCT01677858
- 3.7 NCT00511238
- 6.9 NCT00531284
- 1.8 NCT00531284
- 4.6 NCT00530816
- 8.2 NCT00530816
- 3.5 NCT00511238
- 12.9 NCT01677858
- 1.6 NCT00531284
- 21 NCT01677858
- 1.5 NCT00531284
- 1 NCT00531284
- 11.5 NCT00531284
- 2.9 NCT00531284
- 1.4 NCT00531284
- 4.6 NCT00531284
- 4.6 NCT00531284
- 1.8 NCT00531284
- 1.7 NCT00531284
- 3.8 NCT01775553
- 9.4 NCT00531284
- 13.6 NCT01677858
- 5.2 NCT00531284
- 1.8 NCT00531284
- 5.1 NCT00531284
OS, median
- Bortezomib
- 83.0 vs 53.6vs Velcade, Melphalan and PrednisoneNCT02195479
10 other results
- 49.6 vs 38.5 NCT02136134
- 35.6 vs 31.6 NCT01734928
- 36.7 vs 32.8 NCT03110562
- 41.5 NCT00813150
- 30.8 NCT00103506
- 33 NCT00103506
- 49.8 NCT00507416
- 51.5 NCT00507416
- 53.1 NCT00507416
- 30.8 vs 36.8 NCT00401843
- Carfilzomib
- 10.2 vs 10+0.2 vs placeboNCT01302392
10 other results
- 48.3 vs 40.4 NCT01080391
- 47.6 vs 40 NCT01568866
- 50.8 vs 43.6 NCT03158688
- 15.2 NCT03029234
- 15.4 NCT00511238
- 15.6 NCT00511238
- 37.3 NCT00530816
- 45.6 NCT00530816
- 26 NCT01903811
- 22 NCT01903811
ORR
- Bortezomib
- 90.9% vs 73.9%vs Velcade, Melphalan and PrednisoneNCT02195479
12 other results
- 82.9% vs 63.2% NCT02136134
- 76.4% vs 62.3% NCT03110562
- 70.2% vs 74.4% NCT00813150
- 19% NCT03110562
- 73% NCT00507416
- 80% NCT00507416
- 70% NCT00507416
- 88.1% NCT03412565
- 90.8% NCT03412565
- 55% vs 46.7% NCT00401843
- 80.6% NCT02290431
- 97% NCT03412565
- Carfilzomib
- 82.5%bNCT03859427
56 other results
- 86.3% NCT03859427
- 35.8% NCT03029234
- 87.1% vs 66.7% NCT01080391
- 86.6% vs 82.9% NCT03275285
- 76.9% vs 62.6% NCT01568866
- 84.3% vs 74.7% NCT03158688
- 84.3% vs 78.8% NCT01818752
- 62.9% NCT02412878
- 40.8% NCT02412878
- 35% NCT03029234
- 35.8% NCT03029234
- 35% NCT03029234
- 74.2% NCT01677858
- 76.9% NCT01677858
- 15.4% NCT00531284
- 53% NCT00530816
- 16.1% NCT00530816
- 39.6% NCT00530816
- 88.1% NCT03412565
- 90.8% NCT03412565
- 84.8% NCT03412565
- 66.7% NCT01677858
- 93.3% NCT01677858
- 100% NCT01677858
- 33.3% NCT01677858
- 50% NCT00531284
- 38.5% NCT00531284
- 52.2% NCT00530816
- 17.1% NCT00530816
- 42.4% NCT00530816
- 97% NCT03412565
- 59.2% NCT03934684
- 53.8% NCT03934684
- 97.8% NCT01402284
- 36.4% NCT00531284
- 10% NCT00531284
- 0% NCT00531284
- 100% NCT00531284
- 37.5% NCT00531284
- 28.6% NCT00531284
- 50% NCT00531284
- 64.3% NCT00531284
- 25% NCT00721734
- 37.5% NCT00721734
- 50% NCT00531284
- 0% NCT00531284
- 33.3% NCT00531284
- 42.9% NCT00531284
- 33.3% NCT00531284
- 50% NCT00531284
- 0% NCT00531284
- 18.2% NCT00721734
- 27.3% NCT00721734
- 22.2% NCT00721734
- 100% NCT00531284
- 100% NCT00531284
VGPR or better
- Bortezomib
- 71.1% vs 49.7%vs Velcade, Melphalan and PrednisoneNCT02195479
8 other results
- 59.2% vs 29.1% NCT02136134
- 44.6% vs 32.4% NCT03110562
- 37% NCT00507416
- 51% NCT00507416
- 41% NCT00507416
- 71.6% NCT03412565
- 77.6% NCT03412565
- 80% NCT03412565
- Carfilzomib
- 72.6% vs 56.1%vs Carfilzomib + DexamethasoneNCT03275285
4 other results
- 71.6% NCT03412565
- 77.6% NCT03412565
- 80% NCT03412565
- 77.3% NCT03412565
MRD negativity
- Bortezomib
- 53.3% vs 35.4%vs Bortezomib-lenalidomide-dexamethasone (VRd)NCT03652064
5 other results
- 60.9% vs 39.4% NCT03652064
- 28.3% vs 7% NCT02195479
- 13.5% vs 2.8% NCT02136134
- 25.4% NCT03412565
- 21.5% NCT03412565
- Carfilzomib
- 18.3% vs 5.2%vs Carfilzomib and DexamethasoneNCT03158688
6 other results
- 18.9% NCT03859427
- 18.1% NCT03859427
- 44.4% NCT01402284
- 25.4% NCT03412565
- 21.5% NCT03412565
- 27.3% NCT03412565
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
20 other shared endpoints and safety
Coverage. Bortezomib: 24 of 24 rows · Carfilzomib: 24 of 24 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Bortezomib Rows use multiple source trials | Carfilzomib Rows use multiple source trials |
|---|---|---|
| Complete responder rate · % of participants | 53.1% (n=98) vs 51% (n=96) Thalidomide + Prednisolone @ 52wka,b NCT01539083 · Phase 3 · registry result, not featured evidence · combination 1 other source trial10.7% (n=131) vs 7.3% (n=137) placebo NCT00401843 · Phase 2 · registry result, not featured evidence · combination | 44.1% (n=179) vs 28.5% (n=123) Carfilzomib + Dexamethasonea,b NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 2 other source trials28.5% (n=312) vs 10.4% (n=154) Carfilzomib and Dexamethasone NCT03158688 · Phase 3 · combination 25.9% (n=478) vs 23.1% (n=477) Bortezomib, Melphalan, Prednisone NCT01818752 · Phase 3 · registry result, not featured evidence · combination |
| Complete responder rate · % of participants No placebo or comparator arm | 8.2% (n=73)*c,d,a,e NCT00722566 · Phase 3 · converted to % from 6 Participants as posted show 1 more dose6.2% (n=145)* NCT00722566 · Phase 3 · converted to % from 9 Participants as posted | 21.95% (n=41)Dose Level 3c,d,a,e NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination show 1 more dose17.07% (n=41) @ 14.285714wkDose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination |
| Complete responder rate · % of participants No placebo or comparator arm Complete response | 14.3% (n=7)*f,a,b Complete response NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted | 0% (n=42)*c,f,a,b NCT00511238 · Phase 2 · converted to % from 0 participants as posted show 1 more dose0.4% (n=257)* NCT00511238 · Phase 2 · pooled · converted to % from 1 participants as posted |
| CR/sCR responder rate · % of participants No placebo or comparator arm | 55.2% (n=67)c,a,b NCT03412565 · Phase 2 · registry result, not featured evidence · combination show 2 more doses16.4% (n=67) NCT03412565 · Phase 2 · registry result, not featured evidence · combination 50.8% (n=65) NCT03412565 · Phase 2 · registry result, not featured evidence · combination | 55.2% (n=67)c,a,b NCT03412565 · Phase 2 · combination show 3 more doses16.4% (n=67) NCT03412565 · Phase 2 · combination 42.4% (n=66) NCT03412565 · Phase 2 · combination 50.8% (n=65) NCT03412565 · Phase 2 · combination |
| Duration of Response time to event · months | NA vs 21.3 Velcade, Melphalan and Prednisone monthsa,b NCT02195479 · Phase 3 · registry result, not featured evidence · combination 3 other source trials13.7 vs 10.94 BTZ+LD-DEX months NCT01734928 · Phase 3 · registry result, not featured evidence · combination 17.28 vs 12.88 Bortezomib + Dexamethasone months NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 NA vs NA Lenalidomide+Bortezomib+Dexamethasone months NCT02874742 · Phase 2 · registry result, not featured evidence · combination | 28.6 vs 21.2 Lenalidomide and Dexamethasone (Rd) monthsa,b NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3 4 other source trials7.2 vs 9.5 placebo months NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 NA vs NA Carfilzomib + Dexamethasone months NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 21.3 vs 10.4 Bortezomib months NCT01568866 · Phase 3 · combination NA vs 16.6 Carfilzomib and Dexamethasone months NCT03158688 · Phase 3 · combination |
| Duration of Response time to event · months No placebo or comparator arm | 18.3 monthsc,f,a,b NCT00507416 · Phase 3 · registry result, not featured evidence · combination show 2 more doses19.8 months NCT00507416 · Phase 3 · registry result, not featured evidence · combination 22.4 months NCT00507416 · Phase 3 · registry result, not featured evidence · combination | NA monthsc,f,a,b NCT03412565 · Phase 2 · combination show 2 more dosesNA months NCT03412565 · Phase 2 · combination NA months NCT03412565 · Phase 2 · combination |
| EORTC QLQ-C30 GHS absolute change · score | 9.8 vs 8.9 Velcade, Melphalan and Prednisone score @ 208wka,g NCT02195479 · Phase 3 · registry result, not featured evidence · combination | 65.1 vs 62.9 Bortezomib, Melphalan, Prednisone score @ 48wka,g NCT01818752 · Phase 3 · registry result, not featured evidence · combination |
| Minimal responder rate · % of participants No placebo or comparator arm Minimal response | 14.3% (n=14)*f,a,b Minimal response NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted | 7.1% (n=42)*c,f,a,b NCT00511238 · Phase 2 · converted to % from 3 participants as posted show 1 more dose13.2% (n=257)* NCT00511238 · Phase 2 · pooled · converted to % from 34 participants as posted |
| MRD Negative responder rate · % of participants No placebo or comparator arm | 25.4% (n=67)c,a,b NCT03412565 · Phase 2 · registry result, not featured evidence · combination show 1 more dose21.5% (n=65) NCT03412565 · Phase 2 · registry result, not featured evidence · combination | 25.4% (n=67)c,a,b NCT03412565 · Phase 2 · combination show 2 more doses27.3% (n=66) NCT03412565 · Phase 2 · combination 21.5% (n=65) NCT03412565 · Phase 2 · combination |
| ORR responder rate · % of participants No placebo or comparator arm | 19% (n=63)a,b NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 7 other source trials73% (n=147) NCT00507416 · Phase 3 · registry result, not featured evidence · combination 70% (n=145) NCT00507416 · Phase 3 · registry result, not featured evidence · combination 80% (n=133) NCT00507416 · Phase 3 · registry result, not featured evidence · combination 88.1% (n=67) NCT03412565 · Phase 2 · registry result, not featured evidence · combination 97% (n=67) NCT03412565 · Phase 2 · registry result, not featured evidence · combination 90.8% (n=65) NCT03412565 · Phase 2 · registry result, not featured evidence · combination 80.6% (n=31) @ 24wk NCT02290431 · Phase 2 · registry result, not featured evidence · combination | 62.9% (n=240)20/70 mg/m² once weeklyc,a,b NCT02412878 · Phase 3 · combination show 1 more dose40.8% (n=238)20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination |
| Overall Survival time to event · months No placebo or comparator arm | 33 monthsc,a,b NCT00103506 · Phase 3 · registry result, not featured evidence · combination show 1 more dose30.8 months NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy | NA months20/70 mg/m² once weeklyc,a,b NCT02412878 · Phase 3 · combination show 1 more doseNA months20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination |
| Partial responder rate · % of participants No placebo or comparator arm Partial Response | 28.6% (n=7)*c,f,a,b NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 2 Participants as posted show 2 more doses60% (n=5)* NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted 21.4% (n=14)* NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 3 Participants as posted | 16.7% (n=42)*c,f,a,b NCT00511238 · Phase 2 · converted to % from 7 participants as posted show 1 more dose18.3% (n=257)* NCT00511238 · Phase 2 · pooled · converted to % from 47 participants as posted |
| PFS time to event · months No placebo or comparator arm | 52.8 monthsc,a,e,b NCT02541383 · Phase 3 · registry result, not featured evidence show 1 more dose46.7 months NCT02541383 · Phase 3 · registry result, not featured evidence | 11.2 months20/70 mg/m² once weeklyc,a,e,b NCT02412878 · Phase 3 · combination show 1 more dose7.6 months20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination |
| PFS2 time to event · months | 66.73 vs 42.41 Velcade, Melphalan and Prednisone monthsa,b NCT02195479 · Phase 3 · registry result, not featured evidence · combination | 47.18 vs 35.58 Carfilzomib + Dexamethasone monthsc,a,b NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 show 1 more dose47.18 vs 32.36 Carfilzomib + Dexamethasone months NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 |
| Stable Disease event count · % of participants No placebo or comparator arm Stable disease | 14.3% (n=7)*c,f,a,e,b NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted show 2 more doses20% (n=5)* NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted 7.1% (n=14)* NCT01801436 · Phase 3 · registry result, not featured evidence · converted to % from 1 Participants as posted | 33.3% (n=12)*f,a,e,b Stable Disease NCT01775553 · Phase 2 · registry result, not featured evidence · converted to % from 4 Participants as posted |
| Time to Progression time to event · months | NA vs 19.35 Velcade, Melphalan and Prednisone monthsa,b NCT02195479 · Phase 3 · registry result, not featured evidence · combination 3 other source trialsNA vs 7.29 Bortezomib + Dexamethasone months NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 9.9 vs 12.6 Bortezomib + Dexamethasone months NCT00813150 · Phase 3 · registry result, not featured evidence · combination NA vs NA Lenalidomide+Bortezomib+Dexamethasone months NCT02874742 · Phase 2 · registry result, not featured evidence · combination | NA vs 20.27 Carfilzomib + Dexamethasone monthsa,b NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 1 other source trialNA vs 17.5 Carfilzomib and Dexamethasone months NCT03158688 · Phase 3 · combination |
| Time to Progression time to event · months No placebo or comparator arm | 9.3 monthsc,d,h,b NCT00103506 · Phase 3 · registry result, not featured evidence · combination show 1 more dose6.5 months NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy | 9.4 months20/70 mg/m²c,d,h,b NCT00531284 · Phase 1/2 show 18 more doses1 months20/70 mg/m² NCT00531284 · Phase 1/2 1.6 months20/70 mg/m² NCT00531284 · Phase 1/2 NA months20/70 mg/m² NCT00531284 · Phase 1/2 6.9 months20/56 mg/m² NCT00531284 · Phase 1/2 11.5 months20/56 mg/m² + Dex NCT00531284 · Phase 1/2 · combination NA months20/56 mg/m² NCT00531284 · Phase 1/2 1.6 months20/56 mg/m² NCT00531284 · Phase 1/2 NA months20/56 mg/m² NCT00531284 · Phase 1/2 4.6 months20/45 mg/m² NCT00531284 · Phase 1/2 4.6 months20/45 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 1.6 months20/45 mg/m² NCT00531284 · Phase 1/2 1.6 months45 mg/m² NCT00531284 · Phase 1/2 5.2 months20/36 mg/m² NCT00531284 · Phase 1/2 1.8 months20/36 mg/m² Bolus NCT00531284 · Phase 1/2 1.7 months36 mg/m² NCT00531284 · Phase 1/2 1.8 months20/36 mg/m² Bolus NCT00531284 · Phase 1/2 1.8 months20/27 mg/m² Bolus NCT00531284 · Phase 1/2 5.1 months20 mg/m² Bolus NCT00531284 · Phase 1/2 |
| Time to Response time to event · months | 0.79 vs 0.82 Velcade, Melphalan and Prednisone monthsa,b NCT02195479 · Phase 3 · registry result, not featured evidence · combination 2 other source trials1.41 vs 1.61 Bortezomib + Dexamethasone months NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 0.8 vs 0.8 Lenalidomide+Bortezomib+Dexamethasone months NCT02874742 · Phase 2 · registry result, not featured evidence · combination | 1.4 vs 1.5 Carfilzomib and Dexamethasone monthsa,b NCT03158688 · Phase 3 · combination |
| Time to Response time to event · months No placebo or comparator arm | 1.4 monthsi,a,b NCT02290431 · Phase 2 · registry result, not featured evidence · combination | 2.6 monthsc,i,a,b NCT03934684 · Phase 4 · registry result, not featured evidence · combination show 1 more dose2.8 months NCT03934684 · Phase 4 · registry result, not featured evidence · combination |
| VGPR or Better responder rate · % of participants No placebo or comparator arm | 37% (n=147)c,f,a,b NCT00507416 · Phase 3 · registry result, not featured evidence · combination show 2 more doses41% (n=145) NCT00507416 · Phase 3 · registry result, not featured evidence · combination 51% (n=133) NCT00507416 · Phase 3 · registry result, not featured evidence · combination | 77.6% (n=67)c,f,a,b NCT03412565 · Phase 2 · combination show 3 more doses71.6% (n=67) NCT03412565 · Phase 2 · combination 77.3% (n=66) NCT03412565 · Phase 2 · combination 80% (n=65) NCT03412565 · Phase 2 · combination |
| Dropout rate | 47.3%VELCADE Intravenousj NCT00722566 · Phase 3 show 32 more results45.3%VELCADE Subcutaneous NCT00722566 · Phase 3 n/a: no completion milestone NCT03652064 · Phase 3 · registry result, not featured evidence n/a: no completion milestone NCT02195479 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestone NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination —DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —Treatment 1: POM + BTZ + LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination 1.1%Treatment 1: POM+BTZ+LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneSVd Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —SVdX Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 15%Arm A: VELCADE, CYCLOPHOSPHAMIDE, NCT01146834 · Phase 3 · registry result, not featured evidence 0%Arm B: VELCADE & G-CSF NCT01146834 · Phase 3 · registry result, not featured evidence —Arm E: PLERIXAFOR, VELCADE, & G-CS NCT01146834 · Phase 3 · registry result, not featured evidence · combination 0% NCT01109004 · Phase 3 · registry result, not featured evidence 20.7%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination —Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneDoxil/Caelyx Plus Velcade (Bortezo NCT00103506 · Phase 3 · registry result, not featured evidence · combination n/a: no completion milestoneVelcade (Bortezomib) Monotherapy NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy 70.2%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 68.3%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 74.9%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination 68.1% NCT00813150 · Phase 3 · registry result, not featured evidence · combination 64.3% NCT01801436 · Phase 3 · registry result, not featured evidence 71.6%D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · registry result, not featured evidence · combination 1.5%Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · registry result, not featured evidence · combination 78.5%Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · registry result, not featured evidence · combination 15.4% NCT02874742 · Phase 2 · registry result, not featured evidence · combination 0% NCT02703779 · Phase 2 · registry result, not featured evidence n/a: no completion milestonePart 1 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestonePart 2 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 87.1% NCT02290431 · Phase 2 · registry result, not featured evidence · combination | 1%k NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3 show 68 more results0.6% NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 n/a: no completion milestone NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 —Carfilzomib NCT01568866 · Phase 3 89.7%Carfilzomib + DEX NCT01568866 · Phase 3 · combination 5.4%20/70 mg/m² once weekly NCT02412878 · Phase 3 · combination 8.8%20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination 67.3% NCT03158688 · Phase 3 · combination 71.6%D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · combination 1.5%Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · combination 77.3%Daratumumab + Carfilzomib + Dexame NCT03412565 · Phase 2 · combination 78.5%Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · combination 57.1%20/70 mg/m² NCT00531284 · Phase 1/2 100%20/70 mg/m² NCT00531284 · Phase 1/2 100%20/70 mg/m² NCT00531284 · Phase 1/2 100%20/56 mg/m² NCT00531284 · Phase 1/2 100%20/56 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 100%20/56 mg/m² NCT00531284 · Phase 1/2 100%20/56 mg/m² NCT00531284 · Phase 1/2 100%20/45 mg/m² NCT00531284 · Phase 1/2 85.7%20/45 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 100%20/45 mg/m² NCT00531284 · Phase 1/2 100%45 mg/m² NCT00531284 · Phase 1/2 100%20/36 mg/m² NCT00531284 · Phase 1/2 85.7%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 100%36 mg/m² NCT00531284 · Phase 1/2 96.9%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 100%20/27 mg/m² Bolus NCT00531284 · Phase 1/2 100%20 mg/m² Bolus NCT00531284 · Phase 1/2 91.3%Carfilzomib (A0) NCT00511238 · Phase 2 85%Carfilzomib (A1) NCT00511238 · Phase 2 · pooled 58.6%20/27 mg/m² NCT00530816 · Phase 2 · pooled 74.3%20 mg/m² NCT00530816 · Phase 2 71.2%20 mg/m² NCT00530816 · Phase 2 92.3%Carfilzomib and Dexamethasone (Kd) NCT03934684 · Phase 4 · registry result, not featured evidence · combination 65.3%Carfilzomib, Lenalidomide and Dexa NCT03934684 · Phase 4 · registry result, not featured evidence · combination 16.2%20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination —20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination 78.6% NCT03029234 · Phase 3 · registry result, not featured evidence · combination 41.4% NCT01818752 · Phase 3 · registry result, not featured evidence · combination 0% NCT02969837 · Phase 2 · registry result, not featured evidence — NCT01402284 · Phase 2 · registry result, not featured evidence · combination 11.1%low-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination 19.7%high-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination n/a: no completion milestone NCT01775553 · Phase 2 · registry result, not featured evidence 20.5% NCT01351623 · Phase 2 · registry result, not featured evidence 75%Carfilzomib - Dialysis NCT00721734 · Phase 2 · registry result, not featured evidence 100%Carfilzomib - Mild RI NCT00721734 · Phase 2 · registry result, not featured evidence 80%Carfilzomib - Moderate RI NCT00721734 · Phase 2 · registry result, not featured evidence 66.7%Carfilzomib - Normal RF NCT00721734 · Phase 2 · registry result, not featured evidence 75%Carfilzomib - Severe RI NCT00721734 · Phase 2 · registry result, not featured evidence 0%56mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence 0%45mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence —MTD: Carfilzomib NCT02937571 · Phase 1/2 · registry result, not featured evidence 0%Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 0%Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 0%Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 0%Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 2.8%Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 100%88 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 93.3%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 95.5%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 66.7%56 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 100%45 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | —VELCADE Intravenousj NCT00722566 · Phase 3 show 32 more results—VELCADE Subcutaneous NCT00722566 · Phase 3 — NCT03652064 · Phase 3 · registry result, not featured evidence — NCT02195479 · Phase 3 · registry result, not featured evidence · combination — NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination —DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence —Treatment 1: POM + BTZ + LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination —Treatment 1: POM+BTZ+LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination 0.5%SVd Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —SVdX Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 —Arm A: VELCADE, CYCLOPHOSPHAMIDE, NCT01146834 · Phase 3 · registry result, not featured evidence —Arm B: VELCADE & G-CSF NCT01146834 · Phase 3 · registry result, not featured evidence —Arm E: PLERIXAFOR, VELCADE, & G-CS NCT01146834 · Phase 3 · registry result, not featured evidence · combination — NCT01109004 · Phase 3 · registry result, not featured evidence 5.5%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination —Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination —Doxil/Caelyx Plus Velcade (Bortezo NCT00103506 · Phase 3 · registry result, not featured evidence · combination —Velcade (Bortezomib) Monotherapy NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy 34.5%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 38.9%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 40.1%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination 31.9% NCT00813150 · Phase 3 · registry result, not featured evidence · combination 14.3% NCT01801436 · Phase 3 · registry result, not featured evidence —D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · registry result, not featured evidence · combination —Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · registry result, not featured evidence · combination —Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · registry result, not featured evidence · combination — NCT02874742 · Phase 2 · registry result, not featured evidence · combination — NCT02703779 · Phase 2 · registry result, not featured evidence 33.3%Part 1 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 19%Part 2 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 64.5% NCT02290431 · Phase 2 · registry result, not featured evidence · combination | —k NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3 show 68 more results— NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 16.2% NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 —Carfilzomib NCT01568866 · Phase 3 20.7%Carfilzomib + DEX NCT01568866 · Phase 3 · combination —20/70 mg/m² once weekly NCT02412878 · Phase 3 · combination —20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination — NCT03158688 · Phase 3 · combination —D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · combination —Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · combination —Daratumumab + Carfilzomib + Dexame NCT03412565 · Phase 2 · combination —Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · combination 14.3%20/70 mg/m² NCT00531284 · Phase 1/2 0%20/70 mg/m² NCT00531284 · Phase 1/2 27.3%20/70 mg/m² NCT00531284 · Phase 1/2 33.3%20/56 mg/m² NCT00531284 · Phase 1/2 25%20/56 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 20%20/56 mg/m² NCT00531284 · Phase 1/2 20.8%20/56 mg/m² NCT00531284 · Phase 1/2 0%20/45 mg/m² NCT00531284 · Phase 1/2 0%20/45 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 50%20/45 mg/m² NCT00531284 · Phase 1/2 28.6%45 mg/m² NCT00531284 · Phase 1/2 0%20/36 mg/m² NCT00531284 · Phase 1/2 14.3%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 0%36 mg/m² NCT00531284 · Phase 1/2 10.8%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 25%20/27 mg/m² Bolus NCT00531284 · Phase 1/2 0%20 mg/m² Bolus NCT00531284 · Phase 1/2 28.3%Carfilzomib (A0) NCT00511238 · Phase 2 12.4%Carfilzomib (A1) NCT00511238 · Phase 2 · pooled 10%20/27 mg/m² NCT00530816 · Phase 2 · pooled 17.1%20 mg/m² NCT00530816 · Phase 2 22%20 mg/m² NCT00530816 · Phase 2 —Carfilzomib and Dexamethasone (Kd) NCT03934684 · Phase 4 · registry result, not featured evidence · combination —Carfilzomib, Lenalidomide and Dexa NCT03934684 · Phase 4 · registry result, not featured evidence · combination —20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination —20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination — NCT03029234 · Phase 3 · registry result, not featured evidence · combination 15.5% NCT01818752 · Phase 3 · registry result, not featured evidence · combination — NCT02969837 · Phase 2 · registry result, not featured evidence — NCT01402284 · Phase 2 · registry result, not featured evidence · combination —low-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination —high-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination 7.7% NCT01775553 · Phase 2 · registry result, not featured evidence 9.1% NCT01351623 · Phase 2 · registry result, not featured evidence 37.5%Carfilzomib - Dialysis NCT00721734 · Phase 2 · registry result, not featured evidence 8.3%Carfilzomib - Mild RI NCT00721734 · Phase 2 · registry result, not featured evidence 40%Carfilzomib - Moderate RI NCT00721734 · Phase 2 · registry result, not featured evidence 25%Carfilzomib - Normal RF NCT00721734 · Phase 2 · registry result, not featured evidence 0%Carfilzomib - Severe RI NCT00721734 · Phase 2 · registry result, not featured evidence 0%56mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence 0%45mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence —MTD: Carfilzomib NCT02937571 · Phase 1/2 · registry result, not featured evidence —Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 50%88 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 13.3%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 14.6%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 0%56 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 0%45 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 35.1%VELCADE Intravenousj NCT00722566 · Phase 3 show 32 more results36.1%VELCADE Subcutaneous NCT00722566 · Phase 3 72.1% NCT03652064 · Phase 3 · registry result, not featured evidence 53.8% NCT02195479 · Phase 3 · registry result, not featured evidence · combination 55.1% NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 49.3%DVTd - Part 1 NCT02541383 · Phase 3 · registry result, not featured evidence · combination 18.8%DVTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 27.5%VTd-DARA - Part 2 NCT02541383 · Phase 3 · registry result, not featured evidence 63.7%Treatment 1: POM + BTZ + LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination —Treatment 1: POM+BTZ+LD-DEX NCT01734928 · Phase 3 · registry result, not featured evidence · combination 55.9%SVd Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 42.4%SVdX Arm: Selinexor + Bortezomib + NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 0%Arm A: VELCADE, CYCLOPHOSPHAMIDE, NCT01146834 · Phase 3 · registry result, not featured evidence 0%Arm B: VELCADE & G-CSF NCT01146834 · Phase 3 · registry result, not featured evidence —Arm E: PLERIXAFOR, VELCADE, & G-CS NCT01146834 · Phase 3 · registry result, not featured evidence · combination 20.6% NCT01109004 · Phase 3 · registry result, not featured evidence 34.6%Bortezomib + Cyclophosphamide + De NCT01539083 · Phase 3 · registry result, not featured evidence · combination 27.2%Bortezomib + Thalidomide + Prednis NCT01539083 · Phase 3 · registry result, not featured evidence · combination 37.7%Doxil/Caelyx Plus Velcade (Bortezo NCT00103506 · Phase 3 · registry result, not featured evidence · combination 33%Velcade (Bortezomib) Monotherapy NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy 53.3%Bortezomib and Dexamethasone NCT00507416 · Phase 3 · registry result, not featured evidence · combination 50.9%Bortezomib, Melphalan and Predniso NCT00507416 · Phase 3 · registry result, not featured evidence · combination 58.2%Bortezomib, Thalidomide, and Dexam NCT00507416 · Phase 3 · registry result, not featured evidence · combination 29.8% NCT00813150 · Phase 3 · registry result, not featured evidence · combination 100% NCT01801436 · Phase 3 · registry result, not featured evidence 44.8%D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · registry result, not featured evidence · combination 28.4%Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · registry result, not featured evidence · combination 56.9%Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · registry result, not featured evidence · combination 46.5% NCT02874742 · Phase 2 · registry result, not featured evidence · combination 48% NCT02703779 · Phase 2 · registry result, not featured evidence 47.6%Part 1 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 33.1%Part 2 - Bortezomib + Siltuximab NCT00401843 · Phase 2 · registry result, not featured evidence · combination 45.2% NCT02290431 · Phase 2 · registry result, not featured evidence · combination | 65.3%k NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3 show 68 more results58.6% NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 72.9% NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 58.7%Carfilzomib NCT01568866 · Phase 3 —Carfilzomib + DEX NCT01568866 · Phase 3 · combination 49.6%20/70 mg/m² once weekly NCT02412878 · Phase 3 · combination 43.4%20/27 mg/m² twice weekly NCT02412878 · Phase 3 · combination 68.5% NCT03158688 · Phase 3 · combination 44.8%D + Bortezomib + Melphalan + Predn NCT03412565 · Phase 2 · combination 28.4%Daratumumab (D)+Bortezomib+Lenalid NCT03412565 · Phase 2 · combination 33.3%Daratumumab + Carfilzomib + Dexame NCT03412565 · Phase 2 · combination 56.9%Daratumumab + Lenalidomide + Dexam NCT03412565 · Phase 2 · combination 71.4%20/70 mg/m² NCT00531284 · Phase 1/2 100%20/70 mg/m² NCT00531284 · Phase 1/2 54.5%20/70 mg/m² NCT00531284 · Phase 1/2 33.3%20/56 mg/m² NCT00531284 · Phase 1/2 37.5%20/56 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 50%20/56 mg/m² NCT00531284 · Phase 1/2 45.8%20/56 mg/m² NCT00531284 · Phase 1/2 0%20/45 mg/m² NCT00531284 · Phase 1/2 35.7%20/45 mg/m² + Dex NCT00531284 · Phase 1/2 · combination 83.3%20/45 mg/m² NCT00531284 · Phase 1/2 57.1%45 mg/m² NCT00531284 · Phase 1/2 50%20/36 mg/m² NCT00531284 · Phase 1/2 57.1%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 33.3%36 mg/m² NCT00531284 · Phase 1/2 41.5%20/36 mg/m² Bolus NCT00531284 · Phase 1/2 25%20/27 mg/m² Bolus NCT00531284 · Phase 1/2 33.3%20 mg/m² Bolus NCT00531284 · Phase 1/2 43.5%Carfilzomib (A0) NCT00511238 · Phase 2 47.4%Carfilzomib (A1) NCT00511238 · Phase 2 · pooled 38.6%20/27 mg/m² NCT00530816 · Phase 2 · pooled 34.3%20 mg/m² NCT00530816 · Phase 2 30.5%20 mg/m² NCT00530816 · Phase 2 38.5%Carfilzomib and Dexamethasone (Kd) NCT03934684 · Phase 4 · registry result, not featured evidence · combination 22.4%Carfilzomib, Lenalidomide and Dexa NCT03934684 · Phase 4 · registry result, not featured evidence · combination 37.7%20/56 mg/m^2 once weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination 32.5%20/27 mg/m^2 twice weekly NCT03859427 · Phase 3 · registry result, not featured evidence · combination 55.3% NCT03029234 · Phase 3 · registry result, not featured evidence · combination 49.6% NCT01818752 · Phase 3 · registry result, not featured evidence · combination 39.1% NCT02969837 · Phase 2 · registry result, not featured evidence 42.2% NCT01402284 · Phase 2 · registry result, not featured evidence · combination 39.4%low-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination 47.4%high-dose NCT01903811 · Phase 2 · registry result, not featured evidence · combination 23.1% NCT01775553 · Phase 2 · registry result, not featured evidence 63.6% NCT01351623 · Phase 2 · registry result, not featured evidence 100%Carfilzomib - Dialysis NCT00721734 · Phase 2 · registry result, not featured evidence 66.7%Carfilzomib - Mild RI NCT00721734 · Phase 2 · registry result, not featured evidence 100%Carfilzomib - Moderate RI NCT00721734 · Phase 2 · registry result, not featured evidence 41.7%Carfilzomib - Normal RF NCT00721734 · Phase 2 · registry result, not featured evidence 75%Carfilzomib - Severe RI NCT00721734 · Phase 2 · registry result, not featured evidence 33.3%56mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence 0%45mg/m2/Dose NCT02937571 · Phase 1/2 · registry result, not featured evidence 65.2%MTD: Carfilzomib NCT02937571 · Phase 1/2 · registry result, not featured evidence —Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 100%Dose Level 0 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 33.3%Dose Level 1 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 66.7%Dose Level 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 50%Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 45.7%Phase 2 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination —Dose Level 3 NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 16.7%88 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 26.7%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 39.3%70 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 0%56 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence 33.3%45 mg/m² NCT01677858 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | show 29 more resultsdiarrhoea 56.3% peripheral sensory neuropathy 55.8% neutropenia 54.8% NCT03652064 · Phase 3 · registry result, not featured evidence neutropenia 50.3% thrombocytopenia 49.7% anaemia 31.8% NCT02195479 · Phase 3 · registry result, not featured evidence · combination thrombocytopenia 59.7% peripheral sensory neuropathy 50.2% diarrhoea 36.2% NCT02136134 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 peripheral sensory neuropathy 60.6% constipation 50.6% asthenia 32.8% NCT02541383 · Phase 3 · registry result, not featured evidence · combination bronchitis 40.6% cough 17% nasopharyngitis 17% NCT02541383 · Phase 3 · registry result, not featured evidence bronchitis 36.5% cough 19.4% nasopharyngitis 17.5% NCT02541383 · Phase 3 · registry result, not featured evidence neutropenia 54% peripheral sensory neuropathy 48.2% thrombocytopenia 39.6% NCT01734928 · Phase 3 · registry result, not featured evidence · combination thrombocytopenia 61.5% nausea 50.3% fatigue 42.1% NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 thrombocytopenia 50% anaemia 45.5% nausea 39.4% NCT03110562 · Phase 3 · registry result, not featured evidence · combination · Multiple Myeloma · phase 3 anemia 40% nausea 35% platelet count decreased 35% NCT01146834 · Phase 3 · registry result, not featured evidence platelet count decreased 100% anemia 50% generalized muscle weakness 50% NCT01146834 · Phase 3 · registry result, not featured evidence constipation 35.8% nausea 32.3% peripheral sensory neuropathy 24.4% NCT01539083 · Phase 3 · registry result, not featured evidence · combination upper respiratory tract infection 37.9% peripheral sensory neuropathy 36.9% neuropathy peripheral 29.1% NCT01539083 · Phase 3 · registry result, not featured evidence · combination nausea 47.8% diarrhoea 44.7% fatigue 36.2% NCT00103506 · Phase 3 · registry result, not featured evidence · combination nausea 39.3% diarrhoea 38.4% constipation 30.8% NCT00103506 · Phase 3 · registry result, not featured evidence · monotherapy insomnia 5.5% weight decreased 2.4% blood sodium decreased 1.8% NCT00507416 · Phase 3 · registry result, not featured evidence · combination leukopenia 7.4% platelet count decreased 4.3% insomnia 3.7% NCT00507416 · Phase 3 · registry result, not featured evidence · combination hyperuricaemia 5.1% insomnia 3.8% cough 3.2% NCT00507416 · Phase 3 · registry result, not featured evidence · combination fatigue 38.3% thrombocytopenia 38.3% diarrhoea 36.2% NCT00813150 · Phase 3 · registry result, not featured evidence · combination neutrophil count decreased 78.6% white blood cell count decreased 78.6% platelet count decreased 71.4% NCT01801436 · Phase 3 · registry result, not featured evidence thrombocytopenia 56.7% anaemia 44.8% constipation 44.8% NCT03412565 · Phase 2 · registry result, not featured evidence · combination peripheral sensory neuropathy 41.8% constipation 38.8% neutropenia 37.3% NCT03412565 · Phase 2 · registry result, not featured evidence · combination neutropenia 67.7% diarrhoea 49.2% anaemia 40% NCT03412565 · Phase 2 · registry result, not featured evidence · combination fatigue 71.7% upper respiratory tract infection 67.7% diarrhoea 65.7% NCT02874742 · Phase 2 · registry result, not featured evidence · combination diarrhea 58% (placebo 56.9%) nausea 58% (placebo 64.7%) anorexia 54% (placebo 51%) NCT02703779 · Phase 2 · registry result, not featured evidence neutropenia 81% (placebo 38.1%) diarrhoea 61.9% (placebo 36%) thrombocytopenia 61.9% (placebo 46.8%) NCT00401843 · Phase 2 · registry result, not featured evidence · combination neutropenia 60.6% (placebo 38.1%) thrombocytopenia 58.5% (placebo 46.8%) peripheral sensory neuropathy 51.4% (placebo 52.5%) NCT00401843 · Phase 2 · registry result, not featured evidence · combination diarrhoea 80.6% decreased appetite 58.1% thrombocytopenia 54.8% NCT02290431 · Phase 2 · registry result, not featured evidence · combination | k diarrhoea 43.4% anaemia 42.3% neutropenia 40.1% NCT01080391 · Phase 3 · combination · Multiple Myeloma · phase 3 show 62 more resultsanaemia 56.1% (placebo 47.1%) thrombocytopenia 36.9% (placebo 28.1%) pyrexia 26.1% (placebo 18.3%) NCT01302392 · Phase 3 · monotherapy · Multiple Myeloma · phase 3 infusion related reaction 45.2% upper respiratory tract infection 41.2% diarrhoea 40.7% NCT03275285 · Phase 3 · combination · Multiple Myeloma · phase 3 20/70 mg/m² once weekly anaemia 29% hypertension 24.4% pyrexia 23.1% NCT02412878 · Phase 3 · combination 20/27 mg/m² twice weekly anaemia 31.1% diarrhoea 21.7% hypertension 20.9% NCT02412878 · Phase 3 · combination peripheral sensory neuropathy 41.8% constipation 38.8% neutropenia 37.3% NCT03412565 · Phase 2 · combination 20/56 mg/m² + Dex fatigue 62.5% pyrexia 50% upper respiratory tract infection 50% NCT00531284 · Phase 1/2 · combination 20/45 mg/m² + Dex fatigue 64.3% cough 57.1% upper respiratory tract infection 50% NCT00531284 · Phase 1/2 · combination cough 42.3% anaemia 36.5% pyrexia 26.9% NCT03934684 · Phase 4 · registry result, not featured evidence · combination cough 26.5% diarrhoea 18.4% hypertension 18.4% NCT03934684 · Phase 4 · registry result, not featured evidence · combination 20/56 mg/m^2 once weekly neutropenia 29.1% anaemia 25.1% hypertension 21.5% NCT03859427 · Phase 3 · registry result, not featured evidence · combination 20/27 mg/m^2 twice weekly neutropenia 31.6% hypertension 24.2% anaemia 23.8% NCT03859427 · Phase 3 · registry result, not featured evidence · combination anaemia 61.8% platelet count decreased 48.8% upper respiratory tract infection 48.8% NCT03029234 · Phase 3 · registry result, not featured evidence · combination anaemia 35.4% pyrexia 35.4% nausea 35.2% NCT01818752 · Phase 3 · registry result, not featured evidence · combination fatigue 63% diarrhea 45.7% edema limbs 37% NCT02969837 · Phase 2 · registry result, not featured evidence lymphocyte count decreased 100% hypoalbuminemia 93.3% platelet count decreased 93.3% NCT01402284 · Phase 2 · registry result, not featured evidence · combination low-dose anemia 59.1% fatigue 59.1% platelet count decreased 42.4% NCT01903811 · Phase 2 · registry result, not featured evidence · combination high-dose anemia 66.7% fatigue 57.9% platelet count decreased 50.9% NCT01903811 · Phase 2 · registry result, not featured evidence · combination anemia 61.5% hypertension 53.8% platelet count decreased 53.8% NCT01775553 · Phase 2 · registry result, not featured evidence diarrhea 65.9% nausea 59.1% fatigue 54.5% NCT01351623 · Phase 2 · registry result, not featured evidence anaemia 62.5% thrombocytopenia 62.5% abdominal pain 50% NCT00721734 · Phase 2 · registry result, not featured evidence fatigue 75% anaemia 58.3% constipation 50% NCT00721734 · Phase 2 · registry result, not featured evidence anaemia 62.5% fatigue 50% dyspnoea 37.5% NCT00721734 · Phase 2 · registry result, not featured evidence 56mg/m2/Dose anxiety 33.3% hyperkalemia 33.3% hypertension 33.3% NCT02937571 · Phase 1/2 · registry result, not featured evidence 45mg/m2/Dose lymphocyte count decreased 66.7% skin infection 66.7% alanine aminotransferase increased 33.3% NCT02937571 · Phase 1/2 · registry result, not featured evidence lymphocyte count decreased 73.9% neutrophil count decreased 65.2% white blood cell decreased 60.9% NCT02937571 · Phase 1/2 · registry result, not featured evidence Dose Level 0 anemia 100% cd4 lymphocytes decreased 100% lymphocyte count decreased 100% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination Dose Level 1 anemia 100% lymphocyte count decreased 100% neutrophil count decreased 100% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination Dose Level 2 hypotension 100% lymphocyte count decreased 100% neutrophil count decreased 100% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination Dose Level 3 anemia 100% platelet count decreased 100% white blood cell decreased 100% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination platelet count decreased 100% lymphocyte count decreased 91.4% white blood cell decreased 91.4% NCT01842308 · Phase 1/2 · registry result, not featured evidence · combination 88 mg/m² headache 66.7% fatigue 50% insomnia 50% NCT01677858 · Phase 1/2 · registry result, not featured evidence 70 mg/m² upper respiratory tract infection 80% diarrhoea 60% fatigue 60% NCT01677858 · Phase 1/2 · registry result, not featured evidence 70 mg/m² fatigue 52.8% nausea 40.4% insomnia 32.6% NCT01677858 · Phase 1/2 · registry result, not featured evidence 56 mg/m² anaemia 66.7% arthralgia 66.7% cardiac murmur 66.7% NCT01677858 · Phase 1/2 · registry result, not featured evidence 45 mg/m² fatigue 100% back pain 66.7% diarrhoea 66.7% NCT01677858 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bThe assessment timepoint is not available for both results.
- cThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- dTrial phases differ: Phase 1/2 versus Phase 3.
- eTreatment context has not been resolved for both arms.
- fTrial phases differ: Phase 2 versus Phase 3.
- gAssessment timepoints differ: 48 weeks versus 208 weeks.
- hPopulation context differs: registered conditions differ.
- iTrial phases differ: Phase 4 versus Phase 2.
- jPopulation comparability has not been reviewed for 30 of these studies.
- kPopulation comparability has not been reviewed for 66 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Bortezomib
show 1 more result
show 5 more results
show 1 more result
show 9 more results
show 9 more results
show 9 more results
show 1 more result
show 1 more result
+ 29 further endpoints in the CSV export.
Carfilzomib
show 1 more result
show 1 more result
show 3 more results
+ 93 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Bortezomib's landscape · Carfilzomib's landscape